SCHEMBL1189665

SCHEMBL1189665

CCOC(=O)Nc1cccc(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
LMNA P02545 6/20 0.66
MAPK1 P28482 4/20 0.66
HSD17B10 Q99714 1/20 0.66
TRPV1 Q8NER1 1/20 0.64
MEN1 O00255 5/20 0.63
KMT2A Q03164 5/20 0.63
BLM P54132 3/20 0.63
THRB P10828 2/20 0.63
RECQL P46063 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
HPGD P15428 1/20 0.63
ALOX15 P16050 1/20 0.63
ALDH1A1 P00352 7/20 0.62
TSHR P16473 4/20 0.62
EPHX2 P34913 1/20 0.62
NPC1 O15118 3/20 0.62
RAB9A P51151 3/20 0.62
CYP1A2 P05177 2/20 0.61
CHRM2 P08172 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30599557 1.00 MAPT (0.66) MAPTLMNAMAPK1HSD17B10TRPV1
SCHEMBL11142996 0.89 MEN1 (0.60) MAPTLMNAMAPK1HSD17B10TRPV1
SCHEMBL7565149 0.88 MAPK1 (0.81) MAPTLMNAMAPK1HSD17B10HPGD
SCHEMBL23727571 0.86 TRPV1 (0.56) TRPV1MEN1KMT2ABLMTHRB
SCHEMBL11218133 0.85 EPHX2 (0.79) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL10944813 0.84 HPGD (0.68) MAPTLMNAMAPK1TRPV1MEN1
SCHEMBL11612418 0.84 GPR35 (0.61) MAPTLMNAMAPK1TRPV1MEN1
SCHEMBL11266669 0.84 MEN1 (0.63) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL27898897 0.84 EPHX2 (0.86) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL8885410 0.83 MAPT (0.54) MAPTLMNAMAPK1HSD17B10TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117396473-A Imidazopyridinyl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-12 CN disclosed
CN-115698035-A Inhibitors of norovirus and coronavirus replication 共晶制药公司 2023-02-03 CN disclosed
CN-106008569-A Boronates as arginase inhibitors, compositions and applications thereof 马尔斯公司 2016-10-12 CN disclosed
US-20110155660-A1 MODIFIED MEMBRANE DOW GLOBAL TECHNOLOGIES LLC 2011-06-30 US disclosed
US-7882963-B2 modifying polyamide discriminating layer ( e.g metaphenylene diamine- trimesoyl chloride monomers) with aminoacetophenone or aminothiophenol; fouling resistant surface, improved salt rejection, antimicrobial properties, improved solute, and/or small organics rejection; for water purification DOW GLOBAL TECHNOLOGIES INC. (US) 2011-02-08 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
US-20090159527-A1 MODIFIED MEMBRANE DOW GLOBAL TECHNOLOGIES LLC 2009-06-25 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
WO-2007133362-A1 MODIFIED MEMBRANE DOW GLOBAL TECHNOLOGIES INC. (US) 2007-11-22 WO disclosed
US-6939887-B2 Benzimidazolidinone derivatives SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2005-09-06 US disclosed
US-20040142850-A1 Benzimidazolidinone derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-22 US disclosed
EP-1364945-A1 BENZIMIDAZOLIDINONE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 MAPT 3312/4885LMNA 3250/4885MAPK1 4726/4885
US-20040142850-A1 Benzimidazolidinone derivatives GHSR, GHRHR, PRLHR MAPT 4756/4885LMNA 3672/4885MAPK1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.